Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olinvacimab plus Pembrolizumab in Recurrent Glioblastoma
NCT03722342Phase 1Unknown
- Sponsor
- PharmAbcine
- Start
- Jan 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olinvacimab in glioblastoma (GBM), sponsored by PharmAbcine. Primary endpoints: Dose limiting toxicities, Adverse events up to 2 years and 1 more. Status: unknown.
02
Drugs
olinvacimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03722342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722342.